Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Provention Bio, Washington Prime, Virgin Galactic, and RLX and Encourages Investors to Contact the Firm

In This Article:

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Provention Bio, Inc. (NASDAQ: PRVB), Washington Prime Group, Inc. (NYSE: WPG), Virgin Galactic, Inc. (NYSE: SPCE), and RLX Technology, Inc. (NYSE: RLX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Provention Bio, Inc. (NASDAQ: PRVB)

Class Period: November 2, 2020 to April 8, 2021

Lead Plaintiff Deadline: July 20, 2021

On April 8, 2021, Provention Bio issued a press release “announc[ing] that the Company received a notification on April 2, 2021 from the [FDA], stating that, as part of its ongoing review of the Company’s [BLA] for teplizumab for the delay or prevention of clinical [T1D], the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.”

On this news, Provention's stock price fell $1.73 per share, or 17.78%, to close at $8.00 per share on April 9, 2021.

The complaint alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) Provention Bio’s teplizumab BLA was deficient in its submitted form and would require additional data to secure FDA approval; (ii) accordingly, Provention Bio’s teplizumab BLA lacked the evidentiary support Provention Bio had led investors to believe it possessed; (iii) Provention Bio had thus overstated the teplizumab BLA’s approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, Provention Bio’s public statements were materially false and misleading at all relevant times.

For more information on the Provention Bio class action go to: https://bespc.com/cases/PRVB

Washington Prime Group, Inc. (NYSE: WPG)

Class Period: November 5, 2020 to March 4, 2021

Lead Plaintiff Deadline: July 23, 2021

On February 16, 2021, WPG disclosed that its operating partnership, Washington Prime Group, L.P. (“WPG L.P.”), had “elected to withhold an interest payment of $23.2 million due on February 15, 2021 with respect to WPG L.P.’s outstanding Senior Notes due 2024,” and that “WPG L.P. has a 30-day grace period to make the interest payment before such non-payment constitutes an ‘event of default.’” The Company further advised that, in an event of default, certain counterparties to the senior notes “could accelerate the outstanding indebtedness due . . . making such indebtedness due and payable, which would result in a cross-default with respect to some of WPG L.P.’s or the Company’s other indebtedness.”